Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma

Completed · Phase 1

Conditions studied: Neuroblastoma

In brief

RATIONALE: Biological therapies such as beta-glucan use different ways to stimulate the immune system and stop cancer cells from growing. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining beta-glucan and monoclonal antibody may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining beta-glucan and monoclonal antibody in treating patients who have metastatic neuroblastoma.

Key facts

Study ID

NCT00037011

Run by

Memorial Sloan Kettering Cancer Center

Starts

2001-11-01

Last updated by the study team

2013-01-18

Who can join

Age: any, up to 49. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.